A major goal of research in Parkinson's disease (PD) has been the development of
treatments to slow the progressive degeneration of the nigrostriatal dopaminergic system …

Clinical symptoms of Parkinson's disease (PD) do not manifest until dopamine (DA)
neuronal loss reaches a symptomatic threshold. To explore the mechanisms of functional …

α‐Methyl‐l‐tryptophan (α‐MTrp) is an artificial amino acid and an analog of tryptophan (Trp),
the precursor of the neurotransmitter serotonin (5‐HT). In this article we have summarized …

The development of the striatum dopamine (DA) system through human adolescence, a time
of increased sensation seeking and vulnerability to the emergence of psychopathology, has …

The ability to dynamically use various aspects of cognition is essential to daily function, and
reliant on dopaminergic transmission in cortico-striatal circuitry. Our aim was to investigate …

Objective Patients with Parkinson disease (PD) and mild cognitive impairment (MCI) are
vulnerable to dementia and frequently experience memory deficits. This could be the result …

The recurrent 22q11. 2 deletion is a genetic risk factor for early-onset Parkinson's disease.
Adults with the associated 22q11. 2 deletion syndrome (22q11. 2DS) may exhibit …

Animal data indicate that methamphetamine can damage striatal dopamine terminals. Efforts
to document dopamine neuron damage in living brain of methamphetamine users have …

Background:[18F]-FP-DTBZ has been proven as a biomarker for quantifying the
concentration of presynaptic vesicular monoamine transporter 2 (VMAT2). However, its …

Vesicular monoamine transporter 2 (VMAT2) is a putative molecular target for the
quantitative imaging of pancreatic β-cell mass by PET. The VMAT2 PET tracer 11C …